2-O-acetyl-1,5-anhydro-3,4-dideoxy-D-threo-hexitol | 216098-91-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2-O-acetyl-1,5-anhydro-3,4-dideoxy-D-threo-hexitol
• 英文别名: [(3S,6S)-6-(hydroxymethyl)oxan-3-yl] acetate
• CAS: 216098-91-8
• 化学式: C₈H₁₄O₄
• 分子量: 174.197
• InChiKey: VFIDZWMFCZYRPV-YUMQZZPRSA-N

物化性质

• 沸点：
  266.2±25.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-O-acetyl-1,5-anhydro-3,4-dideoxy-D-threo-hexitol 在 咪唑 、 草酰氯 、 potassium carbonate 、 二甲基亚砜 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1,5-anhydro-3,4-dideoxy-6-O-[(1,1-dimethyl)ethyldimethyl]silyl-D-glycero-hexitolulose
  参考文献：
  名称：

  Synthesis of Methylene-Expanded 2‘,3‘-Dideoxyribonucleosides

  摘要：

  A method for the preparation of methylene-expanded 2',3'-dideoxyribonucleosides is reported. The very inexpensive starting material levoglucosenone 8 was converted into the known mixture of alcohols 12ab which were converted into the required silyl ether alcohol 26 in six steps via either of two routes. The first involved a one-step acetylation and opening of the anhydro sugar bridge to give the triacetates 20ab which were reduced with triethylsilane and silyl triflate to afford the diacetates 21ab, both of which gave 26 after further functional group conversions. The second route entailed a simple acetylation of 12ab followed by reduction with triethylsilane and silyl triflate to give the monoacetates 19ab, both converted via straightforward chemistry into 26. Mesylation of the alcohol of 26 furnished the mesylate 27. Alkylation of adenine with the mesylate 27 afforded the silyl ether 28 which was deprotected to give the desired modified dideoxy nucleoside 7a. Alkylation of 2,6-diaminopurine 38 with the mesylate gave the protected diaminopurine nucleoside 39. Upon acetylation, it produced a mixture of di- and monoacetates 40-41, the latter of which was transformed into the desired guanosine analogue 7e. Thus, two new nucleoside analogues 7ae were prepared from levoglucosenone 8.

  DOI：

  10.1021/jo980436l
• 作为产物：
  描述：

  1,6-anhydro-3,4-dideoxy-β-D-threo/erythro-hex-3-enopyranose 在 Pd-BaSO₄ 吡啶 、 三乙基硅烷 、 lithium aluminium tetrahydride 、 三氟甲磺酸三甲基硅酯 、 氢气 作用下， 以 乙醚 、 二氯甲烷 、 乙腈 为溶剂， 生成 2-O-acetyl-1,5-anhydro-3,4-dideoxy-D-threo-hexitol
  参考文献：
  名称：

  Synthesis of Methylene-Expanded 2‘,3‘-Dideoxyribonucleosides

  摘要：

  A method for the preparation of methylene-expanded 2',3'-dideoxyribonucleosides is reported. The very inexpensive starting material levoglucosenone 8 was converted into the known mixture of alcohols 12ab which were converted into the required silyl ether alcohol 26 in six steps via either of two routes. The first involved a one-step acetylation and opening of the anhydro sugar bridge to give the triacetates 20ab which were reduced with triethylsilane and silyl triflate to afford the diacetates 21ab, both of which gave 26 after further functional group conversions. The second route entailed a simple acetylation of 12ab followed by reduction with triethylsilane and silyl triflate to give the monoacetates 19ab, both converted via straightforward chemistry into 26. Mesylation of the alcohol of 26 furnished the mesylate 27. Alkylation of adenine with the mesylate 27 afforded the silyl ether 28 which was deprotected to give the desired modified dideoxy nucleoside 7a. Alkylation of 2,6-diaminopurine 38 with the mesylate gave the protected diaminopurine nucleoside 39. Upon acetylation, it produced a mixture of di- and monoacetates 40-41, the latter of which was transformed into the desired guanosine analogue 7e. Thus, two new nucleoside analogues 7ae were prepared from levoglucosenone 8.

  DOI：

  10.1021/jo980436l

文献信息

• ９員縮合環誘導体
  申请人：塩野義製薬株式会社

  公开号：JP2016079168A

  公开（公告）日：2016-05-16

  【課題】ＡＣＣ２阻害活性を有する新規化合物の提供。【解決手段】式Ｉで示される置換若しくは非置換の縮合芳香族複素環式基を有する化合物又はその製薬上許容される塩。（式中、Ｒ１は、式：（環Ｂは５員環、環Ｃは６員環）【選択図】なし

  提供具有ACC2抑制活性的新化合物。具有式I中所示的取代或未取代的缩合芳香族复环式基的化合物或其制药上可接受的盐。（其中，R1是，式：（环B是5元环，环C是6元环）【选择图】无
• NOVEL ALKYLENE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：EP3059225A1

  公开（公告）日：2016-08-24

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is -O-(CR6R7)m- etc., -L2- is -O-(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc..

  本发明的目的是提供具有 ACC2 抑制活性的新型化合物。 此外，本发明的目的是提供包含该化合物的药物组合物。 式（I）化合物：其中 R1 是取代或未取代的融合芳香杂环等，环 A 是取代或未取代的非芳香碳环等、 -L1-是-O-(CR6R7)m-等，-L2-是-O-(CR6R7)n-等，每个 R6 和 R7 独立地是氢、卤素等，R2 是取代或未取代的烷基，R3 是氢或取代或未取代的烷基，R4 是取代或未取代的烷基羰基等。
• ACC2 INHIBITORS
  申请人：Shionogi & Co., Ltd.

  公开号：EP3670496A2

  公开（公告）日：2020-06-24

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is -O-(CR6R7)m- etc., -L2- is -O-(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc..

  本发明的目的是提供具有 ACC2 抑制活性的新型化合物。此外，本发明的目的是提供一种包含该化合物的药物组合物。 式(I)的化合物： 其中 R1 是取代或未取代的融合芳香杂环等、 环 A 是取代或未取代的非芳香族碳环等、 -L1-是-O-(CR6R7)m-等、 -L2-是-O-(CR6R7)n-等、 每个 R6 和 R7 独立地是氢、卤素等、 R2 是取代或未取代的烷基、 R3 是氢或取代或未取代的烷基、 R4 是取代或未取代的烷基羰基等。
• 5-phenylazaindole derivative having AMPK-activating activity
  申请人：Shionogi & Co., Ltd.

  公开号：US10478425B2

  公开（公告）日：2019-11-19

  Provided is a compound which is useful as an AMPK activator. The compound is represented by formula: wherein the symbols are defined in the specification.

  本文提供了一种可用作 AMPK 激活剂的化合物。该化合物由式表示： 其中符号在说明书中定义。
• EP3421467
  申请人：——

  公开号：——

  公开（公告）日：——